Hepatitis C
Hepatitis A Immune Response Has Implications for Hepatitis C
- Details
- Category: HCV Basic Science
- Published on Friday, 08 July 2011 13:19
Hepatitis A virus appears to evade immune defenses better than hepatitis C virus, even though it only causes short-term illness. Learning about differences between viral dynamics and immune response to HAV and HCV may offer information that can inform treatment.
Gene Variation Linked to Liver Cancer in Hepatitis C Patients
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 08 July 2011 12:38
A genome-wide association study looking at more than 460,000 single nucleotide changes found that a variation in the DEPDC5 gene on chromosome 22 is associated with increased risk of hepatocellular carcinoma in people with hepatitis C.
Telaprevir Improves Hepatitis C Treatment Response
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 28 June 2011 06:53
The recently approved HCV protease telaprevir added to standard therapy increased cure rates for both previously untreated people and prior non-responders. 
ACH-1625 HCV Protease Inhibitor Starts Phase 2 Trial
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 08 July 2011 00:00
Achillion Pharmaceuticals recently announced that the first patients have started treatment in a Phase 2 clinical trial of the experimental HCV protease inhibitor ACH-1625 plus pegylated interferon and ribavirin.
Vertex Licenses Alios HCV Protease Inhibitors
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:07
Vertex Pharmaceuticals and Alios BioPharma have agreed to collaborate on development of 2 novel nucleotide analog HCV NS5B polymerase inhibitor candidates, now at the preclinical stage.
Primary Care Docs Can Manage Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 05 July 2011 13:07
The ECHO program showed that primary care clinicians can successfully treat underserved hepatitis C patients using video teleconferencing.
Sitges Meeting Discusses European Access to New Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:01
Community activists, researchers, and regulatory and pharmaceutical representatives met this month in Sitges, Spain, to discuss early and expanded access to direct-acting antiviral agents for hepatitis C, especially for difficult-to-treat patients including those with HIV/HCV coinfection and cirrhosis. 
HCV Drug TMC649128 Enters Phase 1b
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 June 2011 07:38
A new HCV polymerase inhibitor, TMC649128, is now being tested in a Phase 1b trial, the first stage of evaluating safety and efficacy in a large number of patients.
HCV Protease Inhibitor Danoprevir Promising in Early Trial
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 14 June 2011 07:54
Experimental HCV protease inhibitor danoprevir (formerly RG7227 and ITMN-191) was safe and showed good antiviral activity at higher doses in a 14-day study of treatment-naive and previously treated genotype 1 chronic hepatitis C patients.
Web Design and Development by